+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacologic modulation of the atherogenic LDL profile in dyslipidemia

Pharmacologic modulation of the atherogenic LDL profile in dyslipidemia

Woodford, F P, Davignon, J, Sniderman, A International Congress Series; Atherosclerosis X 83-87

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 032781419

Download citation: RISBibTeXText

DOI: 10.1016/0021-9150(94)93380-4

Related references

Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy. Clinica e Investigacion en Arteriosclerosis 28(2): 87-93, 2017

The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?. Acta Diabetologica 46(1): 1-11, 2009

Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacology and Therapeutics 101(1): 17-38, 2004

Atherogenic versus non-atherogenic lipoprotein profiles in healthy individuals. is there a need to change our approach to diagnosing dyslipidemia?. Current Medicinal Chemistry 21(25): 2892-2901, 2014

Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. Journal of Cardiovascular Pharmacology 57(2): 267-272, 2011

Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?. Current Pharmaceutical Design 19(21): 3858-3868, 2013

Cholesterol forms and traditional lipid profile for projection of atherogenic dyslipidemia: lipoprotein subfractions and erythrocyte membrane cholesterol. Journal of Membrane Biology 247(2): 127-134, 2014

Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. Journal of Psychopharmacology 26(9): 1201-1210, 2012

Atherogenic dyslipidemia. Indian Journal of Endocrinology and Metabolism 17(6): 969-976, 2013

Obesity and atherogenic dyslipidemia. Gastroenterology 132(6): 2181-2190, 2007

Atherogenic dyslipidemia and oxidative stress: a new look. Translational Research 153(5): 217-223, 2009

The metabolic basis of atherogenic dyslipidemia. Clinical Cornerstone 7(2-3): 27-35, 2005

An update on sarcocystosis in one-humped camels (Camelus dromedarius). Parasitology 145(11): 1367-1377, 2018

Atherogenic dyslipidemia in the cardiometabolic syndrome. Journal of the Cardiometabolic Syndrome 1(2): 153-155, 2006

Atherogenic dyslipidemia: A condition that should not be overlooked. Revista Clinica Espanola 214(9): 513-514, 2014